FDA Grants De Novo to ML-based, Real-time Indicator of Patient Deterioration

Fifth Eye's noninvasive tool is the first to provide continuous monitoring of hemodynamic status using a single ECG lead

March 2, 2021 8:46 AM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

ANN ARBOR, Mich., March 2, 2021 /PRNewswire/ -- Fifth EyeTM, a provider of intuitive real-time clinical analytics, today announced the U.S. Food and Drug Administration (FDA) has granted De Novo classification for its Analytic for Hemodynamic Instability (AHI). AHI can continuously monitor any patient with an electrocardiogram (ECG) for hemodynamic instability — a leading cause of death for critically ill or injured patients. This clinically validated technology enables hemodynamic assessments every two minutes as opposed to every two hours or more, increasing the likelihood of timely patient rescue.

AHI gives a reliable heads-up about emerging signs of hemodynamic instability, enabling proactive patient rescue.

Fifth Eye's machine learning-based software device, developed in collaboration with clinicians at Michigan Medicine, gives nurses and doctors a real-time view into patients' hemodynamic status. AHI automatically provides intuitive, time-trended updates without requiring vital sign assessment, manual data input in electronic health records, or score calculation.

"The current approach to monitoring hemodynamic instability is intermittent, resource intensive, and error prone," said Jen Baird, CEO, Fifth Eye. "AHI is an easy-to-implement device that reduces nurse burden by giving a reliable heads-up about emerging signs of hemodynamic instability that can go undetected with ECG or vital signs alone, enabling proactive patient rescue."

In an FDA-reviewed clinical study, AHI's unstable classifications were highly correlated with hemodynamic instability, defined as hypotension plus tachycardia. AHI identified hemodynamic instability with 96% sensitivity and identified stable patients with 85% specificity compared to traditional vital signs-based reference standards. The results are from over 28,000 AHI outputs across 222 adult critical care patients.

"The problem of predicting unexpected patient decompensation remains critical for hospitals," said Benjamin Bassin, MD, Director, Emergency Critical Care Center, Michigan Medicine. "AHI provides reliable, noninvasive, and continuous monitoring of hemodynamic decompensation by way of ECG waveform analysis — as opposed to intermittent static vital signs — to identify at-risk patients across hospital settings, including remotely. This allows for much earlier intervention and has the potential to improve confidence, quality, safety and appropriate resource allocation across the spectra of U.S. healthcare systems."

The AHI software is intended for use by healthcare professionals managing in-hospital patients 18 years or older who are receiving continuous physiological monitoring with ECG.

About Fifth Eye Inc.

Fifth Eye is a Michigan-based company that develops real-time clinical analytics based on physiologic waveforms. www.fiftheye.com.

Media ContactPatty Keilerpatty@collaborate.health, (312)550-5394

 

Cision View original content:http://www.prnewswire.com/news-releases/fda-grants-de-novo-to-ml-based-real-time-indicator-of-patient-deterioration-301238531.html

SOURCE Fifth Eye Inc



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

PRNewswire, Press Releases

Related Entities

Robert W Baird, FDA